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Abstract 
Background Injecting drug users are at high risk of acquiring blood-borne infections. Ireland has had a 
harm reduction policy of methadone maintenance and needle exchange since 1992. 
Aim To estimate prevalence of hepatitis B, hepatitis C and HIV infection and appropriate uptake of hepatitis 
B vaccine in methadone attendees and to make recommendations for a simple record-based surveillance 
system. 
Method Retrospective study of 138 client records for evidence of laboratory tests or test results for blood-
borne viruses and appropriate immunisation against hepatitis B. 
Results A total of 60% of clients had evidence of one or more laboratory tests in their notes. Of those tested 
for individual viruses, 5.1% were positive for hepatitis B surface antigen, 78.8% had antibodies to hepatitis 
C and 16.7% were HIV positive. Nearly two-thirds of clients had no evidence of vaccination or information 
on prior immunity in their records. 
Conclusions A standardised written protocol for screening for blood-borne viruses and for immunisation 
against hepatitis B in methadone service attendees was clearly needed, and was subsequently introduced by 
the Eastern Region Health Authority. 
 
Introduction 
Injecting drug users are known to be at high risk of 
acquiring blood-borne infections.1-3 Since 1992, the Irish 
Government has actively pursued a policy of harm 
reduction in injecting drug users by providing 
methadone maintenance and needle exchange.4-6 This 
resulted in an increase in the number of opiate users in 
the Eastern Health Board (EHB) region in receipt of 
methadone from 150 in 1992 to just under 3,000 by the 
end of 1997 (715 of whom were attending methadone 
dispensing clinics run by the Health Board). 
 However, information relating to the prevalence 
in these opiate users of the blood-borne diseases, 
hepatitis B (HBV), hepatitis C (HCV) and human 
immunodeficiency virus (HIV), had not been 
comprehensively documented at that time, although 
reports were later published on these infections in 
specific sub-groups of opiate users in 1998.7,8 When this 
survey was undertaken at the end of 1997 there was no 
simple means of ascertaining the prevalence of blood-
borne infections in this client group. 
 The aims of this study were as follows: to 
determine the prevalence of HBV, HCV and HIV in 
opiate users attending methadone clinics in the EHB 
region based on information already available in their 
clinical records; to determine the proportion of 
susceptible opiate users in this population immunised 
against HBV; and to make recommendations on a 
simple surveillance system to enable easier access to 
prevalence data in the EHB Drugs/AIDS Services. 
Method 
The study population was 715 opiate users who were 
attending five dedicated EHB run methadone dispensing 
clinics in December 1997. Following a statistical 
analysis based on the expected prevalence of blood-
borne infections in this population, it was decided that 
taking a randomly selected 20% sample would be 
adequate to achieve a significant result.1,2 To allow for 
initial interview and history taking of new clients, only 
those in the service for at least four weeks were included 
in the survey. Each clinical record was examined on-site 
in the clinics by one of the authors (MF) for a record of 
the blood-borne infections, either in the form of 
laboratory reports or in the hand-written clinical notes 
and letters. Documented information on hepatitis B 
vaccination status was also looked for in the record. 
Data were entered and analysed using Epi Info version 
6.04b.9 
 Hepatitis B virus screening and immunisation in 
people who are not immune should ideally be 
commenced within one month of starting methadone 
and the course of three doses completed within the next 
six months. Therefore, in order to give a realistic 
estimate of hepatitis B vaccination uptake, evidence of- 
immunisation was only looked for in clients who had 
been attending a methadone dispensing clinic for at least 
six months at the time of the study. 
Results 
The records of 143 clients were examined, of whom 138 
had been attending the service for more than four weeks. 
Ninety-nine (72%) of the sample were male. The mean 
age was 29 years (SD ± 6.7) and 45 (32.6%) were under 
25 years. The median duration of attendance in the 
methadone service was eight months. Eighty-three 
(60%) had a laboratory test result for blood-borne 
viruses in the notes. The estimated prevalence of the 
infections, based on laboratory reports seen and a 
combination of those laboratory reports and the hand-
written medical notes, is given in Table 1. 
Evidence of hepatitis B vaccination was only looked for in 
the records of the 85 clients in the sample who had been 
attending a clinic for at least six months (see Table 2). 
Table 1. Blood-borne viral infections in a random sample of 
clients attending EHB methadone clinics in December 1997 
Prevalence in those 
with reported results* 
Test Positive 
Viral marker 
(Number who had test) 
No. % 
Hepatitis B surface antigen (n=79) 4 5.1 
Hepatitis B core antibody (n=64) 18 28.1 
Hepatitis C antibody (n=99) 78 78.8 
HIV antibody (n=90) 15 16.7 
 
*Based on laboratory reports or records’ in medical notes 
Table 2. Hepatitis B vaccination status (as documented in 
medical records) in December 1997 in 85 clients attending 
EHB methadone clinics* 
Description Number % 
Evidence of past infection 
(Hepatitis: B core-antibody +ve) 
15 7.6 
Partially immunized (1-2 doses 
of hepatitis B vaccine given) 
2 2.4 
Fully immunized (3 doses of 
hepatitis B vaccine given) 
13 15.3 
Not vaccinated or information 
on immunity not available 
55 64.7 
 
Total 85 90 
*For six months or more 
Discussion 
This study was carried out in a multidisciplinary 
specialist setting of the health board clinics. These 
clinics are staffed by GPs on a sessional basis, with 
paramedical and clerical support — the primary aim 
being to support methadone replacement. A low level of 
comprehensively documented serological testing for 
blood-borne infections was found and it was difficult to 
establish the prevalence of these diseases accurately. 
Reasons ascertained from the notes for this low level of 
testing included the short time most clients were in the 
service, their high turnover and their mobility due to 
prison sentences and inpatient hospital care. Health 
workers pointed out the difficulties in carrying out blood 
tests when pre-test counselling was required, as this 
often meant the client returning on another day with the 
potential for defaulting. 
 Examination of medical records revealed that 
clients were also less likely to have had a blood test if 
they were described on first interview as “not sharing 
needles” or “not using needles”. There were no agreed 
standard procedures for screening of blood-borne 
viruses in use at the clinics. This highlighted the need 
for a standardised protocol for screening and 
immunisation. 
 The standards of medical records varied 
between centres, and patients’ notes were incomplete in 
some centres. The level of clerical support also varied 
between centres and this may have been reflected in the 
difficulties in maintenance of detailed and complex 
records. An audit of the service such as this highlights 
the difficulties in keeping medical records for a mobile 
population in a primary care setting. Clients attending 
the main methadone dispensing clinics tend to be the 
most chaotic drug users in the system. 
 The prevalence of antibodies to hepatitis B core 
antigen in patients known to have had the test in this 
study was 28.1%, indicating the high level of exposure 
in this group. This is considerably higher than that of 
prisoners who were injecting drugs in another recent 
study of the prevalence of blood-borne infections 
(18.5%).10 
 HCV seroprevalence is very high in this study 
(78.8%), although those under 25 years of age had lower 
recorded prevalence rates (52%). The overall prevalence 
rate is higher than that described by Smyth et al in short-
term injecting drug users in Dublin between 1993 and 
1996 (52.1%)7 and slightly lower than the figure found 
by Allwright et al in drug using Irish prisoners in 1998 
where more than one-third of all prisoners and 80% of 
drug using prisoners were positive for antibodies to 
hepatitis C virus.10 According to their records, clients in 
our study had generally been using drugs over a longer 
duration than the drug users in the study by Smyth et al.7 
The fact that there was no surveillance information “for 
HCV” on a significant percentage (28%) of the study 
population may have also resulted in a higher prevalence 
of HCV, since the clients who have no record of a test 
result might have been those perceived to be less at risk 
or who had tested negative. This desk-based study, 
therefore, has limitations in estimating prevalence rates, 
as possibly those who were most likely to have evidence 
of a test were those with greatest risk of being positive. 
 Estimated prevalence rates for HIV infection in 
this group (16.7%) were higher than those found by 
Dorman et al in 19973 (8.4%) in drug users, and also 
higher than those found by Allwright10 in drug users in 
Irish prisons (3.5%). However, as with HCV, no one 
under 25 years was positive for HIV in the study group, 
indicating the potential for a positive impact of harm 
reduction strategies in younger addicts. 
 Evidence of uptake of hepatitis B vaccination in 
the study group was poor. Even though short-term 
attendees (n=53) were excluded from this part of the 
analysis, only one-third of the remaining 85 clients had 
evidence of either immunity, or partial or full 
immunisation. The remaining two-thirds had either not 
been vaccinated or did not have any record in their notes 
to indicate that they had been vaccinated. Evidence of a 
test to ascertain anti-HBs status after vaccination, as 
recommended by vaccine protocol for the methadone 
service, was also not present in most of the records. 
Vaccine refusals were not recorded. 
 While this study was primarily an audit of 
screening for infectious diseases and immunisation 
practice, it is of limited value in estimating true 
prevalence rates of blood-borne viruses and of practices 
in immunisation. Despite this, the study highlights the 
need for a written standard protocol for screening and 
immunisation in attendees at methadone programmes. 
 High levels of HCV infection reflect the 
infectivity of this virus and the need for early 
intervention in injecting drug users.11 With regard to 
HBV, there is also scope for improve- 
ment in terms of offering screening and immunisation to 
susceptible drug users and their contacts as early as 
possible, with good documentation to flag defaulters to 
other health professionals and outreach workers.12 
 Provision of an accurate surveillance system for 
these infections in this population is complex. The 
logistics of carrying out HTV surveillance in a less 
complex population have been documented.13 Following 
this study, in consultation with the doctors working in 
the ERHA’s Drugs Service, a standard protocol was 
developed for screening their patients for blood-borne 
infectious diseases; it was introduced in October 1998. 
At the same time, a front sheet was developed to go in 
each patient’s records to summarise his or her status 
regarding the screening for blood-borne infections, the 
results of the tests for the various antigens and 
immunisation. 
 The overall aims of implementing this standard 
protocol throughout tile Drugs Service are to improve 
the screening for blood-borne diseases of drug users 
entering the methadone service and to ensure that the 
results of that screening are recorded and then acted 
upon, where appropriate. The protocol proposes that all -
’rug users receiving methadone in the ERHA’s Drugs 
Service should be offered screening for hepatitis B, 
hepatitis C and HIV within four weeks of commencing 
on a methadone programme. If a patient refuses 
screening for one or all of the viruses, it should be 
clearly recorded in the notes giving the reason. The tests 
for hepatitis C and HIV should be repeated annually so 
long as the patient remains negative for these viruses. 
Hepatitis B testing should be done using two serological 
markers, HBsAg and anti-core antibody. If neither of 
these markers is positive, a course of immunisation 
against hepatitis B infection should be offered. Refusals 
should again be recorded. The first dose of 
immunisation should be offered when the negative 
screening results are available with boosters to be given 
at one month and at six months. 
 This protocol has now been implemented 
throughout the ERHA’s Drugs Service and a study is in 
progress to audit its implementation. 
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